Advertisement

Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 600x60px
Document › Details

Epigenomics AG. (10/22/10). "Press Release: Epigenomics AG to Update on Clinical Studies with Septin9 Blood Test for Colorectal Cancer at Two Conferences in Europe and the US". Berlin & Seattle, WA.

Organisation Organisation Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY)
  Group Epigenomics (Group)
Products Product Septin 9 biomarker
  Product 2 colorectal cancer test, early detection (Epigenomics)
Persons Person Beck, Jürgen (Promethera 201512– VP Clinical + Medical Affairs before Boehringer + Synthélabo + Epigenomics + InterMune)
  Person 2 Plum, Achim (Curetis 201505– CCO before Siemens + Epigenomics 200812 SVP Corporate Development)
     


Epigenomics AG, the cancer diagnostics company, today announced that it will present data from two clinical studies with its proprietary biomarker for the blood-based detection of colorectal cancer at two conferences in Europe and the US during the next week.

The two poster presentations will include data form the recently successfully completed prospective PRESEPT Study as well as a follow-up study performed to independently validate the diagnostic assay that had been used in the PRESEPT Study.

On Tuesday, October 26, 2010, Dr. Juergen Beck, M.D., Senior Vice President Medical Affairs at Epigenomics, will present clinical data at the 18th United European Gastroenterology Week (UEGW) in Barcelona, Spain.
J
oseph Romagnuolo M.D., Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at the Medical University of South Carolina will present study data at the American Association for Cancer Research (AACR) Special Conference "Colorectal Cancer: Biology to Therapy" in Philadelphia, PA, USA on Friday, October 29, 2010.

Prof. Romagnuolo participated as a Clinical Investigator in the PRESEPT Study.

Conference Presentation Details

18th United European Gastroenterology Week (UEGW)
October 23-28, 2010
Centre Convencions Internacional Barcelona CCIB
Barcelona, Spain
Poster Presentation:
Poster P0990
October 26, 2010, 9 am - 5 pm

AACR Special Conference "Colorectal Cancer: Biology to Therapy"
October 27- 30, 2010
Loews Philadelphia Hotel
Philadelphia, Pennsylvania, USA
Poster Presentation:
Poster Session B, Board B29
October 29, 2010, 5 pm - 7 pm

- Ends-

Contact Epigenomics AG:

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368
pr@epigenomics.com
www.epigenomics.com

Notes to Editors

About Epigenomics

Epigenomics AG is a molecular diagnostics company with a focus on the development of novel products for cancer. Using DNA methylation biomarkers, Epigenomics' tests on the market and in development for colorectal, lung, and prostate cancer aim at aiding in an earlier and more accurate diagnosis of these diseases thereby potentially increasing the patient's chances of survival.

For development and global commercialization of IVD test products, Epigenomics pursues a dual business strategy in which direct commercialization of proprietary diagnostic test products is combined with non-exclusive licensing to diagnostic industry players with broad customer access. Strategic diagnostics industry partners include Abbott Molecular, Sysmex Corporation, Quest Diagnostics Incorporated, and ARUP Laboratories, Inc. for diagnostics test products and services, and QIAGEN N.V. for sample preparation solutions and research products.

The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more information, please visit Epigenomics' website at www.epigenomics.com.

Epigenomics' legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States of America. The analytical and clinical performance characteristics of any product based on this technology which may be sold at some future time in the USA have not been established.

   
Record changed: 2016-06-15

Advertisement

Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 600x60px

More documents for Epigenomics (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sacura e.tract software 2017 600x60px wptb




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture Sacura e.tract software 2017 120x240px wptb Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px